Current Neuro-Oncology
Volume
26 Number 11
15 June 2024
Home > Publications > Current Neuro-Oncology > Volume 26, Year 2024 > Number 11, 15 June
Barzegar Behrooz A, Darzi Ramandi H, Latifi-Navid H, Peymani P,
Tarharoudi R, Momeni N, Sabaghpour Azarian MM, Eltonsy S,
Pour-Rashidi A, Ghavami S.
Genetic
Prognostic Factors in Adult Diffuse Gliomas: A 10-Year Experience
at a Single Institution.
Cancers
(Basel). 2024 Jun 1;16(11):2121. doi:
10.3390/cancers16112121. PMID:
38893240. Observational study. ˍ
Park
YW, Jang G, Kim SB, Choi K, Han K, Shin NY, Ahn SS, Chang JH, Kim
SH, Lee SK, Jain R.
Leptomeningeal
Metastases in IDH-wildtype Glioblastomas Revisited: Comprehensive
Analysis of Incidence, Risk Factors, and Prognosis Based on
Post-contrast FLAIR.
Neuro
Oncol.
2024 Jun 1:noae091. doi:
10.1093/neuonc/noae091. PMID:
38822538. Observational study˰ ˍ
Dipasquale A, Franceschi E, Giordano L, Maccari M, Barigazzi C, Di
Nunno V, Losurdo A, Persico P, Di Muzio A, Navarria P, Pessina F,
Padovan M, Santoro A, Lombardi G, Simonelli M.
Dissecting
the prognostic signature of patients with astrocytoma isocitrate
dehydrogenase-mutant grade 4: a large multicenter, retrospective
study.
ESMO
Open. 2024 Jun 3;9(6):103485. doi:
10.1016/j.esmoop.2024.103485. PMID:
38833969. Observational study. ˍ
Darlix
A, Monnier M, Castan F, Coutant L, Fabbro M, Denis-Chammas È,
Carrière M, Menjot-de-Champfleur N, Rigau V, Duffau H,
Guerdoux E.
Longitudinal
assessment of quality of life, neurocognition, and psychopathology
in patients with low-grade glioma on first-line temozolomide: A
feasibility study.
Neurooncol
Adv.
2024 Jun 4;6(1):vdae084. doi:
10.1093/noajnl/vdae084. PMID:
38946878. Observational study. ˍ
John
D, Alshalalfa M, Almeida T, Murray A, Marques J, Azzam G, Mellon
EA, Benjamin CG, Komotar RJ, Ivan M, Mahal B, Rich BJ.
Racial
Disparities in Glioblastoma Genomic Alterations: A Comprehensive
Analysis of a Multi-institution Cohort of 2,390 patients.
World
Neurosurg.
2024 Jun 4:S1878-8750(24)00945-8. doi:
10.1016/j.wneu.2024.05.183. PMID:
38843966. Observational study˰ ˍ
Ahluwalia
MS, Ozair A, Drappatz J, Ye X, Peng S, Lee M, Rath S, Dhruv H, Hao
Y, Berens ME, Walbert T, Holdhoff M, Lesser GJ, Cloughesy TF,
Sloan AE, Takebe N, Couce M, Peereboom DM, Nabors B, Wen PY,
Grossman SA, Rogers LR.
Evaluating
the Base Excision Repair Inhibitor TRC102 and Temozolomide for
patients with Recurrent Glioblastoma in the Phase 2 Adult Brain
Tumor Consortium Trial BERT.
Clin
Cancer Res.
2024 Jun 5. doi:
10.1158/1078-0432.CCR-23-4098. PMID:
38836759. Interventional study˰ ˍ
Majd NK, Vo HH, Moran CA, Weathers SP, Song IW, Williford GL,
Rodon J, Fu S, Tsimberidou AM.
Metastatic
extraneural glioblastoma diagnosed with molecular testing.
Oncologist.
2024 Jun 5:oyae115. doi:
10.1093/oncolo/oyae115. PMID:
38837109. Case report. ˍ
*Toyoda M, Shibahara I, Shigeeda R, Fujitani K, Tanihata Y,
Hyakutake Y, Handa H, Komai H, Sato S, Inukai M, Hide T, Shimoda
Y, Kanamori M, Endo H, Saito R, Matsuda KI, Sonoda Y, Kumabe T.
Clinical and molecular features of
patients with IDH1 wild-type primary glioblastoma presenting
unexpected short-term survival after gross total resection.
J
Neurooncol. 2024 Jun 5. doi:
10.1007/s11060-024-04687-2. PMID:
38839702. Observational
study˰ ˍ
Arrieta VA, Gould A, Kim KS, Habashy KJ, Dmello C,
Vázquez-Cervantes GI, Palacín-Aliana I, McManus G,
Amidei C, Gomez C, Dhiantravan S, Chen L, Zhang DY, Saganty R,
Cholak ME, Pandey S, McCord M, McCortney K, Castro B, Ward R,
Muzzio M, Bouchoux G, Desseaux C, Canney M, Carpentier A, Zhang B,
Miska JM, Lesniak MS, Horbinski CM, Lukas RV, Stupp R, Lee-Chang
C, Sonabend AM.
Ultrasound-mediated
delivery of doxorubicin to the brain results in immune modulation
and improved responses to PD-1 blockade in gliomas.
Nat
Commun. 2024 Jun 6;15(1):4698. doi:
10.1038/s41467-024-48326-w. PMID:
38844770. Translational study; Observational study. ˍ
Chen
Y, Van Deventer D, Nianogo R, Vinceti M, Kang W, Cockburn M,
Federman N, Heck JE.
Maternal
exposure to heavy metals from industrial sources during pregnancy
and childhood cancer risk in California.
J
Occup Environ Med.
2024 Jun 6. doi:
10.1097/JOM.0000000000003160. PMID:
38845100. Observational study˰ ˍ
Chuthip
P, Sitthinamsuwan B, Witthiwej T, Tansirisithikul C, Khumpalikit
I, Nunta-Aree S.
Predictors
for the Differentiation between Glioblastoma, Primary Central
Nervous System Lymphoma, and Metastasis in Patients with a
Solitary Enhancing Intracranial Mass.
Asian
J Neurosurg.
2024 Jun 6;19(2):186-201. doi:
10.1055/s-0044-1787051. PMID:
38974428. Observational study. ˍ
Zhang Y, Luo X, Zhu Y, Zhang Q, Liu B.
Differentiation
between primary central nervous system lymphomas and gliomas
according to pharmacokinetic parameters derived from dynamic
contrast-enhanced magnetic resonance imaging.
Heliyon.
2024 Jun 6;10(12):e32619. doi:
10.1016/j.heliyon.2024.e32619. PMID:
38952379.
Observational study. ˍ
Joh-Carnella N, Bauman G, Yock TI, Zelcer S, Youkhanna S,
Cacciotti C.
Case report: Pediatric
low-grade gliomas: a fine balance between treatment options,
timing of therapy, symptom management and quality of life.
Front
Oncol. 2024 Jun 7;14:1366251. doi:
10.3389/fonc.2024.1366251. PMID:
38912055. Case report. ˍ
Preusser
M, Kazda T, Le Rhun E, Sahm F, Smits M, Gempt J, Koekkoek JA,
Monti AF, Csanadi M, Pitter JG, Bulbek H, Fournier B, Quoilin C,
Gorlia T, Weller M, Minniti G; European Organisation for Research,
Treatment of Cancer (EORTC) Brain Tumor Group.
Lomustine
with or without reirradiation for first progression of
glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a
randomized phase III study.
Trials.
2024 Jun 7;25(1):366. doi:
10.1186/s13063-024-08213-7. PMID:
38849943. Interventional study protocol. ˍ
Nguyen
MP, Almiron Bonnin D, Mirchia K, Chen WC, Goldschmidt E,
Braunstein SE, Perry A, Raleigh DR, Oberheim Bush NA.
Response
to immune checkpoint inhibition in a meningioma with DNA mismatch
repair deficiency.
Neurooncol
Adv.
2024 Jun 8;6(1):vdae092. doi:
10.1093/noajnl/vdae092. PMID:
38957162. Case report. ˍ
Würtemberger
U, Diebold M, Rau A, Akgün V, Becker L, Beck J, Reinacher PC,
Taschner CA, Reisert M, Fehrenbacher L, Erny D, Scherer F,
Hohenhaus M, Urbach H, Demerath T.
Advanced
diffusion imaging reveals microstructural characteristics of
primary CNS lymphoma, allowing differentiation from glioblastoma.
Neurooncol
Adv.
2024 Jun 8;6(1):vdae093. doi:
10.1093/noajnl/vdae093. PMID:
38946879. Observational study. ˍ
Xue B, Hou Z, Deng Z, Sun S, Zhang C, Pan Y, Zhang Y, Li Z, Xie J.
Survival outcome and predictors of WHO
grade 2 and 3 insular gliomas: A classification based on the tumor
spread.
Cancer
Med. 2024 Jun 8;13(11):e7377. doi:
10.1002/cam4.7377. PMID:
38850123. Observational study. ˍ
Casile M, Thivat E, Giraudet F, Ginzac A, Molnar I, Biau J,
Brehant J, Lourenco B, Avan P, Durando X.
Non-invasive
intracranial pressure monitoring for high-grade gliomas patients
treated with radiotherapy: results of the GMaPIC trial.
Front
Oncol. 2024 Jun 11;14:1302977. doi:
10.3389/fonc.2024.1302977. PMID:
38919520.
Interventional study. ˍ
*Jia F, Kang Y, Wang Z.
Case report: A
53-year-old woman with synchronous WHO classification II and IV
gliomas.
Front
Oncol. 2024 Jun 11;14:1308497. doi:
10.3389/fonc.2024.1308497. PMID:
38919539. Case report. ˍ
Lecce M, Rasile F, Tanzilli A, Gaviani P, Mariantonia C, Villani
V, Pace A, Terrenato I, Casini B, Novello M, Telera S.
Second
surgery for relapsed glioblastoma: an observational study on
criteria for patient selection in real life.
Future
Oncol. 2024 Jun 11:1-9. doi:
10.1080/14796694.2024.2358743? PMID:
38861296. Observational study˰
ˍ
Minea
RO, Thein TZ, Yang Z, Campan M, Ward PM, Schönthal AH, Chen
TC.
NEO212,
temozolomide conjugated to NEO100, exerts superior therapeutic
activity over temozolomide in preclinical chemoradiation models of
glioblastoma.
Neurooncol
Adv.
2024 Jun 11;6(1):vdae095. doi:
10.1093/noajnl/vdae095. PMID:
39022643. Laboratory investigation. ˍ
Pan C, Zhang M, Xiao X, Li T, Liu Z, Wang Y, Xie L, Mai Y, Wu Z,
Zhang J, Zhang L.
Brainstem Gliomas
With Isocitrate Dehydrogenase Mutation: Natural History,
Clinical-Radiological Features, Management Strategy, and Long-Term
Outcome.
Neurosurgery.
2024 Jun 11. doi:
10.1227/neu.0000000000003020. PMID:
38860769. Observational study˰
ˍ
Oki S, Ishi Y, Sawaya R, Okamoto M, Motegi H, Tanei ZI, Tsuda M,
Mori T, Nishioka K, Kanno-Okada H, Aoyama H, Tanaka S, Yamaguchi
S, Fujimura M.
Clinical outcome,
radiological findings, and genetic features of IDH-mutant
brainstem glioma in adults.
Acta
Neurochir (Wien). 2024 Jun 12;166(1):263. doi:
10.1007/s00701-024-06154-3. PMID:
38864949. Observational study˰
ˍ
Yang Y, Wadhwani N, Shimomura A, Zheng S, Chandler J, Lesniak MS,
Tate MC, Sonabend AM, Kalapurakal J, Horbinski C, Lukas R, Stupp
R, Kumthekar P, Sachdev S.
Long-term
outcomes of central neurocytoma - an institutional experience.
J
Neurooncol. 2024 Jun 12. doi:
10.1007/s11060-024-04713-3. PMID:
38865011. Observational study˰
ˍ
Flies
CM, Snijders TJ, De Leeuw BI, van Maren EA, Kersten BJP, Verhoeff
JJC, De Vos FYF, Robe PA, Hendrikse J, Dankbaar JW.
The
Differentiation between Progressive Disease and Treatment-Induced
Effects with Perfusion-Weighted Arterial Spin-Labeling in
High-Grade Gliomas.
AJNR
Am J Neuroradiol.
2024 Jun 13. doi:
10.3174/ajnr.A8336. PMID:
38871374. Observational study˰ ˍ
Fu P, Shen J, Song K, Xu M, Zhou Z, Xu H.
Prognostic
Factors for Recurrent Glioma: A Population-Based Analysis.
Clin
Med Insights Oncol. 2024 Jun 13;18:11795549241252652.
doi:
10.1177/11795549241252652. PMID:
38883848. Observational study. ˍ
*Ryu
S, Ye X, Olson JJ, Mikkelsen T, Bangiyev L, Lesser GJ, Batchelor
T, Nabors B, Desideri S, Walbert T, Grossman SA.
Phase
I and pharmacodynamic study of arsenic trioxide plus radiotherapy
in patients with newly diagnosed glioblastoma.
Neurooncol
Adv.
2024 Jun 13;6(1):vdae089. doi:
10.1093/noajnl/vdae089. PMID:
38978961. Interventional
study. ˍ
Yuan C, Cheng Z, Liu Y, You Y, Wang L, Li D, Zhong L.
Incidence
and risk factors of post-operative delirium in glioma patients: A
prospective cohort study in general wards.
J
Clin Nurs. 2024 Jun 13. doi:
10.1111/jocn.17326. PMID:
38867617. Observational study˰
ˍ
Nelson
MV, Kim A, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey BD,
Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Ramirez NC, Jaju
A, Fox E, Weigel BJ, Hawkins DS, Mooney MM, Takebe N, Tricoli JV,
Janeway KA, Seibel NL, Parsons DW.
Phase
II study of vemurafenib in children and young adults with tumors
harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial
(APEC1621) Arm G.
Oncologist.
2024 Jun 14:oyae119. doi:
10.1093/oncolo/oyae119. PMID:
38873934. Interventional study. ˍ
Shi Y, Kang X, Ge Y, Cao Y, Li Y, Guo X, Chen W, Guo S, Wang Y,
Liu D, Wang Y, Xing H, Xia Y, Li J, Wu J, Liang T, Wang H, Liu Q,
Jin S, Qu T, Li H, Yang T, Zhang K, Feng F, Wang Y, You H, Ma W.
The molecular signature and prognosis
of glioma with preoperative intratumoral hemorrhage: a
retrospective cohort analysis.
BMC
Neurol. 2024 Jun 14;24(1):202. doi:
10.1186/s12883-024-03703-2. PMID:
38877400. Observational study. ˍ
Sloan
AE, Winter K, Gilbert MR, Aldape K, Choi S, Wen PY, Butowski N,
Iwamoto FM, Raval RR, Voloschin AD, Kamiya-Matsuoka C, Won M,
Mehta MP.
NRG-BN002:
Phase I Study of Ipilimumab, Nivolumab, and the Combination in
Patients with Newly Diagnosed GBM.
Neuro
Oncol.
2024 Jun 14:noae058. doi:
10.1093/neuonc/noae058. PMID:
38874333. Interventional study˰ ˍ
Aqamour
R, Leknani M, Nasri S, Kamaoui I, Skiker I.
Peritoneal
metastasis of a cerebellar medulloblastoma through a
ventriculoperitoneal shunt: A case report.
Radiol
Case Rep.
2024 Jun 15;19(9):3610-3612. doi:
10.1016/j.radcr.2024.05.021. PMID:
38983304. Case report. ˍ
Gupta A, Gupta P, Chatterjee D, Gupta N, Bhatia V.
Extracranial
metastasis from a frontal embryonal tumor to the parotid:
Cytomorphologic features of a rare occurrence.
Diagn
Cytopathol. 2024 Jun 15. doi:
10.1002/dc.25370. PMID:
38877851. Case report˰
ˍ
Lakomý
R, Lojová M, Souckova L, Hynkova L, Polachova K, Vasina J,
Demlová R, Poprach A, Sana J, Prochazka T, Smrcka M, Fadrus
P, Jancalek R, Selingerova I, Belanova R, Slampa P, Pospisil P,
Kazda T.
11C-methionine
in the diagnostics and management of glioblastoma patients with
rapid early progression: nonrandomized, open label, prospective
clinical trial (GlioMET).
BMC
Cancer.
2024 Jun 15;24(1):736. doi:
10.1186/s12885-024-12469-2. PMID:
38879476. Interventional study protocol. ˍ